Abaloparatide (Effective 12/2021, Box Warning has been removed)

Risk of Osteosarcoma (Effective 12/2021, Box Warning has been removed)

• Abaloparatide caused a dose-dependent increase in the incidence of osteosarcoma, a malignant bone tumor, in male and female rats. It is unknown whether TYMLOS will cause osteosarcoma in humans. 
• Use of TYMLOS is not recommended in patients at increased risk for osteosarcoma.   
• Cumulative use of TYMLOS and parathyroid hormone analogs (e.g., teriparatide) for more than 2 years during a patient’s lifetime is not recommended. 

Patient Counseling Information

• TYMLOS

Medication Guides

Patient Medication Guide

Package Inserts

Abaloparatide